Kaleido Biosciences, Inc. (NASDAQ:KLDO) Sees Significant Drop in Short Interest

Kaleido Biosciences, Inc. (NASDAQ:KLDOGet Rating) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 1,400,000 shares, a decline of 40.2% from the March 31st total of 2,340,000 shares. Approximately 7.3% of the company’s shares are sold short. Based on an average daily volume of 5,070,000 shares, the short-interest ratio is presently 0.3 days.

A number of research analysts have issued reports on the company. Chardan Capital cut Kaleido Biosciences from a “buy” rating to a “neutral” rating and decreased their target price for the company from $3.00 to $1.70 in a research note on Monday, April 4th. Zacks Investment Research raised Kaleido Biosciences from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a research note on Tuesday, April 12th.

Several institutional investors have recently modified their holdings of KLDO. Wells Fargo & Company MN raised its holdings in Kaleido Biosciences by 1,291.2% during the fourth quarter. Wells Fargo & Company MN now owns 13,022 shares of the company’s stock worth $31,000 after acquiring an additional 12,086 shares in the last quarter. Barclays PLC raised its holdings in Kaleido Biosciences by 108.5% during the third quarter. Barclays PLC now owns 7,920 shares of the company’s stock worth $43,000 after acquiring an additional 4,122 shares in the last quarter. D. E. Shaw & Co. Inc. bought a new stake in Kaleido Biosciences during the fourth quarter worth about $45,000. Dimensional Fund Advisors LP bought a new stake in Kaleido Biosciences during the third quarter worth about $57,000. Finally, Renaissance Technologies LLC raised its holdings in Kaleido Biosciences by 32.1% during the fourth quarter. Renaissance Technologies LLC now owns 39,374 shares of the company’s stock worth $94,000 after acquiring an additional 9,574 shares in the last quarter. Institutional investors own 81.56% of the company’s stock.

Shares of Kaleido Biosciences stock opened at $0.05 on Friday. The firm has a market cap of $2.13 million, a price-to-earnings ratio of -0.02 and a beta of -0.06. The stock’s 50-day moving average is $1.10 and its 200-day moving average is $2.45. Kaleido Biosciences has a one year low of $0.04 and a one year high of $0.13.

About Kaleido Biosciences (Get Rating)

Kaleido Biosciences, Inc, a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease.

Read More

Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.